How GLP-1 went from being a hard-to-handle hormone to a blockbuster success

IF 122.7 1区医学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Nature Reviews. Drug Discovery Pub Date : 2024-11-01 DOI:10.1038/d41573-024-00177-2

Asher Mullard

引用次数: 0

Abstract

Lotte Bjerre Knudsen, chief scientific advisor in research and early development at Novo Nordisk, discusses the past and future of GLP-1s and related anti-obesity drugs. Lotte Bjerre Knudsen, chief scientific advisor in research and early development at Novo Nordisk, discusses the past and future of GLP-1s and related anti-obesity drugs.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

GLP-1 如何从一种难以驾驭的激素变成成功的大片

诺和诺德公司研究和早期开发首席科学顾问 Lotte Bjerre Knudsen 讨论了 GLP-1s 和相关抗肥胖药物的过去和未来。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Nature Reviews. Drug Discovery 医学-生物工程与应用微生物

CiteScore

137.40

自引率

0.30%

发文量

227

期刊介绍： Nature Reviews Drug Discovery is a monthly journal aimed at everyone working in the drug discovery and development arena. Each issue includes: Highest-quality reviews and perspectives covering a broad scope. News stories investigating the hottest topics in drug discovery. Timely summaries of key primary research papers. Concise updates on the latest advances in areas such as new drug approvals, patent law, and emerging industry trends and strategies.

期刊最新文献

FDA approves L-amino acid decarboxylase deficiency gene therapy. Benchmarking recruitment rates for phase III trials Antimalarial drug hits cardiac fibrosis JAK inhibition combats adverse skin reaction Lundbeck pays US$2.6 billion for Longboard and its lead epilepsy drug